JMP Securities Reiterates Market Outperform on Rallybio, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating on Rallybio (NASDAQ:RLYB) and maintained an $8 price target on the stock.
April 19, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirms Rallybio's Market Outperform rating and $8 price target.
The reiteration of a Market Outperform rating and an $8 price target by JMP Securities for Rallybio suggests a positive outlook on the stock by the analyst. This could lead to increased investor confidence and potentially drive Rallybio's stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100